573 related articles for article (PubMed ID: 15955104)
1. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept.
Lizzul PF; Aphale A; Malaviya R; Sun Y; Masud S; Dombrovskiy V; Gottlieb AB
J Invest Dermatol; 2005 Jun; 124(6):1275-83. PubMed ID: 15955104
[TBL] [Abstract][Full Text] [Related]
2. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24.
Wang F; Smith N; Maier L; Xia W; Hammerberg C; Chubb H; Chen C; Riblett M; Johnston A; Gudjonsson JE; Helfrich Y; Kang S; Fisher GJ; Voorhees JJ
Br J Dermatol; 2012 Jul; 167(1):92-102. PubMed ID: 22458549
[TBL] [Abstract][Full Text] [Related]
3. TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept.
Caldarola G; De Simone C; Carbone A; Tulli A; Amerio P; Feliciani C
Int J Immunopathol Pharmacol; 2009; 22(4):961-6. PubMed ID: 20074459
[TBL] [Abstract][Full Text] [Related]
4. Infliximab restores the balance between pro- and anti-apoptotic proteins in regressing psoriatic lesions.
Kokolakis G; Giannikaki E; Stathopoulos E; Avramidis G; Tosca AD; Krüger-Krasagakis S
Br J Dermatol; 2012 Mar; 166(3):491-7. PubMed ID: 21985184
[TBL] [Abstract][Full Text] [Related]
5. Etanercept restores a differentiated keratinocyte phenotype in psoriatic human skin: a morphological study.
Donetti E; Gualerzi A; Ricceri F; Pescitelli L; Bedoni M; Prignano F
Exp Dermatol; 2012 Jul; 21(7):549-51. PubMed ID: 22716254
[TBL] [Abstract][Full Text] [Related]
6. Nature of cell kinetics in psoriatic epidermis.
Doger FK; Dikicioglu E; Ergin F; Unal E; Sendur N; Uslu M
J Cutan Pathol; 2007 Mar; 34(3):257-63. PubMed ID: 17302610
[TBL] [Abstract][Full Text] [Related]
7. Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin.
Johansen C; Flindt E; Kragballe K; Henningsen J; Westergaard M; Kristiansen K; Iversen L
J Invest Dermatol; 2005 Jun; 124(6):1284-92. PubMed ID: 15955105
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of action of etanercept in psoriasis.
Tan JK; Aphale A; Malaviya R; Sun Y; Gottlieb AB
J Investig Dermatol Symp Proc; 2007 May; 12(1):38-45. PubMed ID: 17502868
[TBL] [Abstract][Full Text] [Related]
9. Etanercept for psoriasis: two case reports.
Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
[TBL] [Abstract][Full Text] [Related]
10. Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment.
de Groot M; Teunissen MB; Picavet DI; de Rie MA; Bos JD
Exp Dermatol; 2010 Aug; 19(8):754-6. PubMed ID: 20482616
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of survivin and NF-kappaB in psoriasis, an immunohistochemical study.
Abdou AG; Hanout HM
J Cutan Pathol; 2008 May; 35(5):445-51. PubMed ID: 18005174
[TBL] [Abstract][Full Text] [Related]
12. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober BE; Clarke S
J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
[TBL] [Abstract][Full Text] [Related]
13. Etanercept for the treatment of psoriasis and psoriatic arthritis.
Gottlieb AB
Dermatol Ther; 2004; 17(5):401-8. PubMed ID: 15379775
[TBL] [Abstract][Full Text] [Related]
14. Targeting NF-kappa B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis.
Wang H; Syrovets T; Kess D; Büchele B; Hainzl H; Lunov O; Weiss JM; Scharffetter-Kochanek K; Simmet T
J Immunol; 2009 Oct; 183(7):4755-63. PubMed ID: 19752240
[TBL] [Abstract][Full Text] [Related]
15. CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept.
Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Stramazzotti D; Morichetti D; Bernardini ML; Mannello B; Fabris G; Offidani A
Br J Dermatol; 2007 Dec; 157(6):1155-60. PubMed ID: 17916208
[TBL] [Abstract][Full Text] [Related]
16. Expression of tumor necrosis factor-α and nuclear factor-kappaB/RelA and the pathogenesis of psoriasis.
Moorchung N; Vasudevan B; Mani NS; Verma R
Indian J Pathol Microbiol; 2014; 57(2):205-8. PubMed ID: 24943751
[TBL] [Abstract][Full Text] [Related]
17. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
Mease PJ
Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
[TBL] [Abstract][Full Text] [Related]
18. Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept.
Giunta A; Babino G; Manetta S; Mazzotta A; Chimenti S; Esposito M
Drug Dev Res; 2014 Nov; 75 Suppl 1():S27-30. PubMed ID: 25381970
[TBL] [Abstract][Full Text] [Related]
19. Etanercept does not have an apoptosis-inducing effect on psoriatic keratinocytes.
Tatlican S; Arikok A; Gulbahar O; Eren C; Cevirgen B; Eskioglu F
J Dermatolog Treat; 2010 Sep; 21(5):306-10. PubMed ID: 19878038
[TBL] [Abstract][Full Text] [Related]
20. Luteolin inhibits human keratinocyte activation and decreases NF-κB induction that is increased in psoriatic skin.
Weng Z; Patel AB; Vasiadi M; Therianou A; Theoharides TC
PLoS One; 2014; 9(2):e90739. PubMed ID: 24587411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
